Home › Bile Duct Cancer
Bile Duct Cancer clinical trials recruiting in the U.S.
12 studies for Bile Duct Cancer are recruiting participants at sites across the United States.
Bile duct cancer can be caused by liver diseases or colitis. Learn about bile duct cancer tests, diagnosis, treatment, and survival rates.
Cities with the most studies
By state
Recently updated studies
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT04645160Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RecruitingObservational study
Ages 2 and older · All sexes · Updated Sep 8, 2026 · NCT01915225Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories
RecruitingPhase 4
Ages 21 and older · All sexes · Updated Sep 3, 2026 · NCT07120295PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Sep 2, 2026 · NCT05286814A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07186842Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05874414Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Jul 13, 2026 · NCT05000294Integrated Cancer Repository for Cancer Research
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT05655949A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Mar 24, 2026 · NCT05849480Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Recruiting
Ages 18 to 99 · All sexes · Updated Feb 20, 2026 · NCT04907643EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
Recruiting
Ages 18 to 100 · All sexes · Updated Apr 1, 2024 · NCT06340620From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.